Key result
Tirofiban plus cilostazol improves 1-month clinical efficacy by ~18 percentage points over standard DAPT.
Why the study?
Patients with ACS face persistent risks of myocardial under-perfusion and adverse events after PCI, and although combining tirofiban and cilostazol has shown potential efficacy, clinical validation in elderly ACS patients remained limited.
Does the combination of tirofiban and cilostazol improve clinical effectiveness, cardiac function recovery, and reduce major adverse cardiovascular events compared to standard aspirin and clopidogrel in elderly patients with acute coronary syndrome undergoing PCI?
RCT (n=80)
Single-blind (outcome assessors blinded; treating physicians not blinded)
1:1 ratio using a computer-generated random number sequence with sealed opaque envelopes
No
Does the combination of tirofiban and cilostazol improve clinical effectiveness, cardiac function recovery, and reduce major adverse cardiovascular events compared to standard aspirin and clopidogrel in elderly patients with acute coronary syndrome undergoing PCI?
In elderly ACS patients undergoing PCI, treatment with intravenous tirofiban and oral cilostazol significantly improved 1-month cardiac function, reduced systemic inflammation and platelet aggregation, and lowered MACE rates (2.50% vs 22.50%) compared to standard aspirin and clopidogrel therapy.
Answers are grounded in this paper and cite their sources.
Supports tirofiban-cilostazol over standard DAPT in elderly ACS-PCI patients; extends RCT evidence for intensified antiplatelet regimens.
BACKGROUND Acute coronary syndrome (ACS) is a prevalent cardiovascular disease with persistent risks of myocardial under-perfusion and adverse events after percutaneous coronary intervention (PCI). The combination of tirofiban and cilostazol has shown potential efficacy, but clinical validation remains limited. This study evaluated the effects of tirofiban combined with cilostazol on cardiac function recovery and prognosis in elderly ACS patients after PCI. MATERIAL AND METHODS This study included 80 elderly ACS patients treated between April 2020 and April 2022. Patients were assigned to the control group (n=40), receiving aspirin and clopidogrel, or the observation group (n=40), receiving tirofiban and cilostazol after PCI. We assessed cardiac function, myocardial markers, serum inflammatory factors, platelet aggregation rate, platelet count (PLT), quality-of-life scores, and the incidence of major adverse cardiovascular events (MACE). RESULTS The treatment effectiveness was 97.50% in the observation group versus 80.00% in the control group. One month after PCI, the observation group had lower left ventricular end-diastolic diameter and left ventricular end-systolic diameter and higher left ventricular ejection fraction. Inflammatory markers (IL-6, hs-CRP, TNF-alpha), platelet aggregation rate, and PLT levels were significantly decreased. Myocardial markers (CK-MB, hs-cTnT) were elevated at 24 hours but improved by 1 month. Quality-of-life scores improved significantly, and MACE incidence was lower in the observation group. CONCLUSIONS Tirofiban combined with cilostazol enhances cardiac function, reduces inflammation, platelet aggregation, and myocardial injury, and improves prognosis in elderly ACS patients after PCI.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2025) conducted an RCT in Acute coronary syndrome undergoing percutaneous coronary intervention (n=80). Tirofiban combined with cilostazol vs. Aspirin 100 mg and clopidogrel 75 mg orally once daily (plus conventional drug treatments) was evaluated on Total clinical effective rate at 1 month after PCI (p=0.001). Tirofiban combined with cilostazol increased the 1-month total effective rate to and reduced major cardiovascular events incidence to compared to aspirin and clopidogrel.
Synapse has enriched 10 related papers. Consider them for comparative context: